DUBLIN–(BUSINESS WIRE)–The “Cell Therapy Manufacturing Market by Type of Cell Manufactured, Source of Cell, Scale of Operation, Purpose of Manufacturing and Key Geographical Regions – Industry Trends and Global Forecasts, 2021-2030” report has been added to ResearchAndMarkets.com’s offering.
This report features an extensive study of the current market landscape and future opportunities associated with cell therapy manufacturing, along with information on both contract manufacturers, as well as developers having in-house production capabilities, offering in-depth analyses of the various business entities engaged in this domain, across key global regions.
Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry. In fact, in February 2021, the USFDA approved Breyanzi, a CAR-T cell-based therapy, developed by Bristol Myers Squibb, which is designed to treat relapsed or refractory large B-cell lymphoma. According to a recent report (published by The Alliance for Regenerative Medicine), over 1,200 clinical trials, focused on the evaluation of cell therapies, gene therapies and tissue-based therapies, are currently being conducted by over 1,000 organizations (including academic institutions), worldwide.
Further growth of the market is primarily hindered by the limited availability of expertise, lack of specialized infrastructure to produce cell therapies, and several product development and manufacturing related challenges. With a sufficient body of evidence, validating the clinical benefits / therapeutic potential of this complex class of biologic drugs, the focus of stakeholders in this industry segment has now shifted to optimizing the cell therapy manufacturing process. Moreover, as more big pharma players enter this field of research, there is likely to be a substantial rise in the cell therapy manufacturing demand, as the proprietary product candidates of these large companies mature and need to be mass produced. In order to address the concerns related to manufacturing, several cell therapy developers (including the larger companies) have turned to contract manufacturing organizations (CMOs).
The cell therapy manufacturing service landscape features a mix of industry players (including well-established companies, mid-sized firms and start-ups / small companies), as well as several academic institutes. It is worth highlighting that innovator companies that have the required capabilities and facilities to produce cell therapies for in-house requirements, also offer contract services (primarily to ensure the optimum use of their resources and open up additional revenue generation opportunities).
Further, in order to make cell therapies more affordable, several stakeholders are integrating various degrees of automation to cut down on labor costs and also improve process scalability. This specialty services industry has witnessed significant partnership activity over the past few years, with several companies being acquired by the larger firms, in efforts to grow and consolidate their capabilities in this space. As stakeholders strive to mitigate existing challenges and focus on innovation to improve the cell production process, we believe that the market will witness significant growth in mid-long term.
- 3P Biopharmaceuticals
- A2 Biotherapeutics
- A2 Healthcare
- Abeona Therapeutics
- Achilles Therapeutics
- Adva Biotechnology
- Advanced Cell Therapy Laboratory, Yale School of Medicine
- Advent Bioservices
- AGC Biologics
- Agenus (AgenTus Therapeutics)
- Akron Biotech
- Alberta Cell Therapy Manufacturing (ACTM)
- Allele Biotechnology and Pharmaceuticals
- Allogene Therapeutics
- apceth Biopharma
- Aspire Health Science
- Astellas Pharma
- Asterias Biotherapeutics
- Astero Bio (acquired by BioLife Solutions)
- Atara Biotherapeutics
- Autolus Therapeutics
- Bay City Capital
- Bellicum Pharmaceuticals
- Bio Elpida
- BioInno Bioscience
- BioNTech IMFS
- Biopharmaceutical Development Program, National Cancer Institute
- BioRestorative Therapies
- BioTherapeutics Unit, Netherlands Cancer Institute
- bluebird bio
- BlueRock Therapeutics (acquired by Bayer)
- Bone Therapeutics
- BrainStorm Cell Therapeutics
- Brammer Bio
- BriaCell Therapeutics
- Bristol Myers Squibb
- And Many More Companies!
Key Questions Answered
- What is the current, annual, global demand for cell-based therapies? How is the demand for such products likely to evolve over the next decade?
- What is the current, installed contract manufacturing capacity for cell therapies?
- What are the key parameters governing the price of cell therapies?
- What are the key recent developments (such as partnerships and expansions) in this industry?
- What kind of partnership models are commonly adopted by stakeholders engaged in this domain?
- What are the different initiatives undertaken by big pharma players for the manufacturing of cell therapies in the recent past?
- What different types of automated technology platforms available for the development and manufacturing of cell therapies?
- Who are the key players (industry / non-industry) engaged in the manufacturing of cell-based therapies across the world?
- What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to cell therapies?
- How is the current and future market opportunity likely to be distributed across key market segments?
Key Topics Covered:
2. EXECUTIVE SUMMARY
4. MARKET OVERVIEW
5. REGULATORY LANDSCAPE
6. ROADMAPS FOR OVERCOMING CHALLENGES
7. AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING
8. PROFILES: INDUSTRY PLAYERS
9. PROFILES: NON-INDUSTRY PLAYERS
10. ROLE OF NON-PROFIT ORGANIZATIONS
12. FACILITY EXPANSIONS
13. BIG PHARMA INITIATIVES
14. CAPACITY ANALYSIS
15. DEMAND ANALYSIS
16. COST PRICE ANALYSIS
17. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
18. MARKET SIZING AND OPPORTUNITY ANALYSIS
19. KEY INSIGHTS
20. SWOT ANALYSIS
21. CONCLUDING REMARKS
22. SURVEY ANALYSIS
23. INTERVIEW TRANSCRIPTS
24. APPENDIX 1: TABULATED DATA
25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/r9f7rp
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900